{"id":"W3087393791","doi":"10.1016/s0140-6736(20)31953-x","title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1060,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Atezolizumab; Anthracycline; Oncology; Chemotherapy; Internal medicine; Placebo; Nab-paclitaxel; Breast cancer; Triple-negative breast cancer; Paclitaxel; Stage (stratigraphy); Cancer; Immunotherapy; Pembrolizumab; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02791968987241577,"score_gpt":0.308306646219802,"score_spread":0.2803869563473863,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}